Overview
- TickerENLV on Nasdaq1
- Industrybiotechnology1
- HeadquartersNess Ziona1
- Founded inIsrael1
- Websitewww.enlivex.com
- Legal formlimited company, public company1
- Listed onNasdaq (ENLV), Tel Aviv Stock Exchange (ENLV)1
- Incorporated inIsrael5
- Business address37 Dereh Menachem Begin St., 15Th Floor, Tel Aviv5
- Filer categoryNon-accelerated filer5
See how the biggest companies compare on our leaderboards
Enlivex R&D changed its name to Enlivex Therapeutics Ltd., and upon consummation of the Merger, to Enlivex Therapeutics R&D Ltd.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $4.0M7 | $5.6M8 | $6.1M9 | $12.9M10 | $18.7M11 | $19.0M4 | $10.6M4 | $9.2M4 |
| Operating expenses | $19.3M10 | $25.8M11 | $29.4M4 | $15.9M4 | $15.0M4 | |||
| Operating income | -$5.3M7 | -$8.6M8 | -$9.8M9 | -$19.3M10 | -$25.8M11 | -$29.4M4 | -$15.9M4 | -$15.0M4 |
| Income before tax | $14.5M8 | -$29.1M4 | -$15.0M4 | $1.6B4 | ||||
| Income tax | -$4.0K12 | $382.6M4 | ||||||
| Net income | -$4.2M7 | -$9.4M8 | -$11.8M9 | -$14.5M10 | -$31.1M11 | -$29.1M4 | -$15.0M4 | $1.2B4 |
| Earnings per share | -$0.909 | -$0.8110 | -$1.6911 | -$1.564 | -$0.734 | $27.044 | ||
| Earnings per share (diluted) | -$0.909 | -$0.8110 | -$1.6911 | -$1.564 | -$0.734 | $25.484 | ||
| Shares (weighted, basic) | 17.9M shares10 | 18.4M shares11 | 18.6M shares4 | 20.5M shares4 | 45.7M shares4 | |||
| Shares (weighted, diluted) | 17.9M shares10 | 18.4M shares11 | 18.6M shares4 | 20.5M shares4 | 48.5M shares4 |
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash | $9.7M13 | $3.9M7 | $5.7M8 | $11.2M9 | $49.9M10 | $813.0K11 | $3.3M4 | $1.9M4 |
| Current assets | $10.3M13 | $16.4M7 | $38.1M8 | $86.4M9 | $52.3M10 | $33.8M11 | $26.0M4 | $1.7B4 |
| Property, plant and equipment | $2.5M9 | $9.9M10 | $1.5M11 | $625.0K4 | $361.0K4 | |||
| Total assets | $11.0M13 | $17.6M7 | $40.4M8 | $95.1M9 | $67.6M10 | $36.8M11 | $27.7M4 | $2.3B4 |
| Current liabilities | $1.1M13 | $6.0M7 | $4.4M8 | $4.7M9 | $6.6M10 | $6.1M11 | $3.8M4 | $9.0M4 |
| Long-term liabilities | $5.4M9 | $4.2M10 | $686.0K11 | $299.0K4 | $383.0M4 | |||
| Total liabilities | $1.3M13 | $6.3M7 | $4.9M8 | $10.1M9 | $10.8M10 | $6.7M11 | $4.1M4 | $392.1M4 |
| Retained earnings | -$52.0M9 | -$83.0M10 | -$112.1M11 | -$127.1M4 | $1.1B4 | |||
| Shareholders’ equity | $9.7M8 | $11.3M9 | $35.5M10 | $85.0M11 | $56.8M4 | $30.1M4 | $23.6M4 | $1.9B4 |
| Shares outstanding | 420.6K shares12 | 10.3M shares13 | 14.6M shares7 | 18.3M shares8 | 18.4M shares9 | 18.6M shares10 | 23.7M shares11 | 237.4M shares4 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -$3.2M7 | -$7.0M8 | -$11.0M9 | -$17.5M10 | -$24.0M11 | -$23.5M4 | -$13.0M4 | -$10.4M4 |
| Stock-based compensation | $2.9M10 | $2.7M11 | $2.0M4 | $2.1M4 | $1.8M4 | |||
| Capital spending | $461.0K7 | $193.0K8 | $1.0M9 | $1.6M10 | $8.1M11 | $236.0K4 | $103.0K4 | $68.0K4 |
| Free cash flow | -$3.6M | -$7.2M | -$12.0M | -$19.2M | -$32.1M | -$23.8M | -$13.1M | -$10.5M |
| Cash from investing | -$38.4M10 | $62.5M11 | -$26.0M4 | $9.1M4 | -$1.3M4 | |||
| Cash from financing | $61.0M10 | $150.0K11 | $360.0K4 | $6.5M4 | $10.4M4 |
Leadership
Who has led Enlivex, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2010201520202025
- Chief executive officerOren Hershkovitz Mar 18, 2026 to now14
- Chief financial officerShachar Shlosberger Mar 18, 2026 to now15
Board members and other officers (5)
- Chief Medical OfficerEinat Galamidi Mar 18, 2026 to now16
- Board memberAvraham Havron Mar 18, 2026 to now17
- Board memberGili Hart Mar 18, 2026 to now18
- Board memberRoger Pomerantz Mar 18, 2026 to now19
- Board memberShai A. Novik Mar 18, 2026 to now20
Former names
Timeline
Filings
188 filings to the SEC since October 2021: 5 annual reports, 7 insider forms, 5 large holders, 171 other. The latest 20:
- Oct 2, 20266-K/A AMENDMENT NO. 2 TO FORM 6-K EDGAR
- Oct 1, 20266-K/A CURRENT REPORT EDGAR
- Sep 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 17, 2026424B3 PROSPECTUS EDGAR
- Aug 13, 2026EFFECT EDGAR
- Aug 13, 2026SCHEDULE 13G EDGAR
- Aug 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 6, 2026F-3 REGISTRATION STATEMENT EDGAR
- Jul 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 13, 20266-K EDGAR
- Jul 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
The 188 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Lind Partners LLCSCHEDULE 13G, 1 filing Aug 13, 202621
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 4 filings Nov 14, 2024 to Aug 14, 202522
Links
- Websitewww.enlivex.com1
- WikidataQ96480089
- SEC EDGARCIK 1596812
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataEnlivex on Wikidata
- 2SEC EDGAREnlivex filings on SEC EDGAR
- 3Company websiteEnlivex logo
- 4SEC EDGAREnlivex 10-K for fiscal 2025
- 5SEC EDGAREnlivex filings on SEC EDGAR
- 6
- 7SEC EDGAREnlivex 10-K for fiscal 2018
- 8SEC EDGAREnlivex 10-K for fiscal 2019
- 9SEC EDGAREnlivex 10-K for fiscal 2020
- 10SEC EDGAREnlivex 10-K for fiscal 2021
- 11SEC EDGAREnlivex 10-K for fiscal 2022
- 12SEC EDGAREnlivex 10-K for fiscal 2018
- 13SEC EDGAREnlivex 10-K for fiscal 2018
- 14
- 15
- 16
- 17SEC EDGARAvraham Havron, Board member
- 18SEC EDGARGili Hart, Board member
- 19SEC EDGARRoger Pomerantz, Board member
- 20SEC EDGARShai A. Novik, Board member
- 21
- 22